Robert W. Baird Remains a Buy on Inspire Medical Systems (INSP)

Inspire Medical Systems, Inc. (NYSE:INSP) is one of the top oversold NYSE stocks to buy now. Robert W. Baird analyst David Rescott maintained a Buy rating on Inspire Medical Systems, Inc. (NYSE:INSP) on August 5, setting a price target of $150.00.

A medical professional performing a minimally invasive procedure while using the company’s technology.

The rating update came after Inspire Medical Systems, Inc.’s (NYSE:INSP) release of its fiscal Q2 2025 earnings on August 4.

Inspire Medical Systems, Inc. (NYSE:INSP) generated $217.1 million in revenue in fiscal Q2 2025, reflecting an 11% rise over the same quarter last year. Gross margin for the quarter reached 84.0%, while net loss was $3.6 million.

The company reported $13.3 million in adjusted net income, while adjusted diluted earnings per share were $0.45 for fiscal Q2 2025.

Inspire Medical Systems, Inc. (NYSE:INSP) also announced the initiation of the full launch of the Inspire V neurostimulation system in the United States.

Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company that develops and commercializes innovative, minimally invasive solutions for obstructive sleep apnea.

The company offers Inspire therapy, which includes implantable components with a pressure-sensing lead, a stimulation lead, and a neurostimulator, operable through a remote control.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.